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Abstract — Aims: The aims were to provide proofs of mechanism and principle by establishing the ability of kynurenine metab-
olites to inhibit the liver mitochondrial low Km aldehyde dehydrogenase (ALDH) activity after administration and in vivo, and to
induce aversion to alcohol. Methods: Kynurenic acid (KA), 3-hydroxykynurenine (3-HK) and 3-hydroxyanthranilic acid (3-HAA)
were administered to normal male Wistar rats and ALDH activity was determined both in vitro in liver homogenates and in vivo (by
measuring blood acetaldehyde following ethanol administration). Alcohol consumption was studied in an aversion model in rats and
in alcohol-preferring C57 mice. Results: ALDH activity was significantly inhibited by all three metabolites by doses as small as 1
mg/kg body wt. Blood acetaldehyde accumulation after ethanol administration was strongly elevated by KA and 3-HK and to a
lesser extent by 3-HAA. All three metabolites induced aversion to alcohol in rats and decreased alcohol preference in mice.
Conclusions: The above kynurenine metabolites of tryptophan induce aversion to alcohol by inhibiting ALDH activity. An intellec-
tual property covering the use of 3-HK and 3-HAA and derivatives thereof in the treatment of alcoholism by aversion awaits further
development.
INTRODUCTION
It is generally accepted that the most effective relapse pre-
venting drugs following detoxification of alcohol-dependent
subjects are the N-methyl-D-aspartate modulator acampro-
sate, the μ-opioid receptor antagonist naltrexone and the
aldehyde dehydrogenase (ALDH) inhibitor and alcohol aver-
sion drug disulfiram (Mann, 2004). The superiority of disul-
firam over acamprosate and naltrexone has been
demonstrated (see, e.g. de Sousa and de Sousa, 2004, 2005;
Laaksonen et al., 2008; Diehl et al., 2010). However, safety
issues with disulfiram (Chick, 1999) suggest the need for
developing safer alternative ALDH inhibitors for alcoholism
treatment. One such alternative may be the essential amino
acid L-tryptophan (Trp) and its metabolites.
Of all amino acids, Trp has been the most extensively
studied in relation to alcohol and alcoholism. While Trp
metabolism and disposition are greatly influenced by acute
and chronic alcohol (ethanol) consumption and subsequent
withdrawal in both humans and experimental animals (for
reviews, see Le Marquand et al., 1994a, b; Badawy, 2002,
2005), Trp itself can also influence alcohol consumption.
Thus, alcohol consumption by rats is decreased by Trp and
its 5-hydroxylated metabolite, although the Trp effect is con-
troversial (for review and references, see Naranjo et al.,
1986). The implication of serotonin (5-hydroxytryptamine or
5-HT) as a modulator of alcohol consumption has arisen
from a variety of studies using treatments influencing the
metabolism and function of this indolylamine, such as its
Trp and 5-hydroxytryptophan precursors, the Trp hydroxyl-
ase inhibitor p-chlorophenylalanine, various serotonin
reuptake inhibitors, serotonin postsynaptic receptor activators
and neurotoxic destruction of serotonin neurons, (reviewed
by Naranjo et al., 1986; Sellers et al., 1992). Accordingly, it
has always been assumed that the decrease in alcohol con-
sumption by Trp is mediated by serotonin, although no
mechanistic studies were performed to confirm this assump-
tion. An alternative or additional mechanism is that of Trp
acting peripherally via its metabolites to induce aversion.
Thus, we have previously reported (Badawy and Morgan,
2007) that a number of Trp metabolites of the quantitatively
most important of the Trp-degradative pathways (the hepatic
kynurenine pathway; Fig. 1), namely 3-hydroxykynurenine
(3-HK), 3-hydroxyanthranilic acid (3-HAA) and kynurenic
acid (KA), and also the Trp transamination product
indol-3-ylpyruvic acid (IPA) strongly inhibit the activity of
the mammalian (rat) liver mitochondrial low Km ALDH in
vitro.A t2μM, inhibition by these four metabolites was 55,
46, 40 and 30% respectively, against a 42% inhibition by a
similar concentration of the classical AlDH inhibitor
disulfiram. Less strong inhibition was also observed with
the kynurenine metabolite xanthurenic acid and with
5-hydroxytryptophan and it is of interest that inhibition of
alcohol consumption by this immediate serotonin precursor
has been suggested to involve a peripheral, in addition to a
central and component (Zabik et al., 1994). In the present
paper, we demonstrate the ability of the former three kynure-
nine metabolites to: (a) inhibit ALDH activity after adminis-
tration to rats; (b) elevate blood acetaldehyde concentration
following acute ethanol administration; (c) induce aversion
to alcohol in an experimental aversion model and (d)
decrease alcohol preference in mice, and propose these
metabolites as potential alcohol aversion drugs. The Trp
transamination metabolite IPA was not included in the
present work because of its back-conversion into Trp
(Richards et al., 1972).
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Chemicals and other materials
Bovine albumin, disulfiram (tetraethyl thiuram disulfide),
ethanol (>99%), oxidized nicotinamide-adenine dinucleotide
(NAD)
+, Trp, 3-HK, 3-HAA, KA and other kynurenine
metabolites were purchased from the Sigma-Aldrich Co Ltd.
(Fancy Road, Poole, Dorset, UK) and were stored as directed
by the manufacturer. Water and methanol [high-performance
liquid-chromatographic (HPLC) grade] were purchased from
either VWR International (Hunter Boulevard, Magna Park,
Leicestershire, UK) or Fisher Scientific UK (Bishop
Meadow Road, Loughborough, Leicestershire, UK). Acids
and alkalis were purchased from VWR International, were of
the purest commercially available grades and were made up
in HPLC-grade water. Filtration, Eppendorf and other tubes
were purchased from Fisher or other standard suppliers.
Animals and treatments
Adult normal male Wistar rats weighing between 150 and
170 g at the start of experiments were purchased from accre-
dited animal suppliers and were acclimatized to our standard
UK Home Office-approved housing conditions (21 ±2°C,
relative humidity of 55± 10% and a 12 h/12 h light: dark
cycle) for at least one week before experiments. They were
housed five per cage, unless stated otherwise, in convention-
al open-top cages with standard softwood bedding from
accredited suppliers, and were allowed free access to stan-
dard laboratory RM1 diet and water. Adult male mice of the
alcohol-preferring C57BL/6J strain, weighing between 20
and 22 g at the start of experiments were also investigated.
This study was performed under the auspices of Cardiff
University and approved and licensed (project licence No:
PPL 30/2502) by the UK Home Office under the Animal
(Scientific Procedures) Act 1986. All compounds were admi-
nistered intraperitoneally in 0.9% (w/v) NaCl (physiological
saline) or, in the case of disulfiram, in a mixture of dimethyl-
formamide: saline (1:1). 3-HK, 3-HAA and KA were given
in single doses of 1–10 mg/kg body wt, whereas disulfiram
was given in a 100 mg/kg dose. When given repeatedly for
up to 8 days, these compounds were given in the above
single doses once daily.
Determination of ALDH activity
The mitochondrial low Km ALDH activity was determined
by the method of Tottmar et al. (1973) in rat liver super-
natants prepared as described by Mazzanti et al. (1989).
Briefly, a 1 g piece of frozen liver was homogenized in 9 ml
of an ice-cold homogenization buffer consisting of 0.25 M
sucrose, 5 mM Tris–HCl and 0.5 mM ethylene-diamine tetra-
acetic acid disodium salt (pH 7.2) for 1 min using an
ultra-Turrax homogenizer. The homogenate was centrifuged
at 500g for 15 min at 4°C. The decanted supernatant was
treated with 0.4 ml of a 5% aqueous sodium deoxycholate
solution, stirred gently and made up to 10 ml with the above
homogenization buffer. For assay of the low Km ALDH
activity, the 1 ml total incubation mixture contained the fol-
lowing components in their final concentrations: NAD
+ (1
mM), pyrazole (0.1 mM), rotenone (2 μM), sodium pyropho-
sphate buffer, pH 8.8 (50 mM), acetaldehyde (5 μM) and
0.1 ml of the above liver supernatant. Before the addition of
acetaldehyde, the mixture was preincubated for 10 min at
25°C. The reaction was then started by the addition of acet-
aldehyde followed by incubation at 25°C for 5 min with
shaking, and was terminated by placing the incubation tubes
on ice. The reduced nicotinamide-adenine dinucleotide
formed was determined by measuring its absorption at 340
nm against a blank preincubated and incubated as above, but
to which water was added instead of acetaldehyde. Blanks
were performed in duplicates, whereas tests were in tripli-
cates. ALDH activity was expressed in μmol of NADH
formed/min per mg of protein. The latter was determined by
the method of Lowry et al. (1951), using bovine serum
albumin as standard. In initial experiments, the high Km
ALDH activity was also determined in the presence of a 5
mM acetaldehyde concentration.
Determination of ALDH activity in vivo
ALDH activity in vivo was determined by measuring blood
acetaldehyde concentration following acute ethanol adminis-
tration. The recovery of acetaldehyde from rat blood is best
achieved by haemolysis of the blood sample, rather than by
acid precipitation (Eriksson et al., 1977; Eriksson, 1980).
Rats received an intraperitoneal injection of kynurenine
metabolites (10 mg/kg body wt each). One hour later,
another injection of ethanol (2 g/kg body wt as a 25% v/v
solution in physiological saline) was administered. Blood
samples (100 μl each) were withdrawn at hourly intervals for
Fig. 1. Diagram of the hepatic kynurenine pathway adapted from Badawy
(2002) with kind permission.
652 Badawy et al.3 h after the ethanol injection from a tail vein under light iso-
fluorane anaesthesia and immediately added to 0.9 ml of
ice-cold water in a gas-chromatographic (GC) injection vial.
The vial was immediately sealed using a crimper and the
contents of the vial were mixed. The vials were subsequently
stored in a refrigerator at 4°C overnight before analysis the
following morning. Acetaldehyde and ethanol in the sealed
vials were analyzed by head-space GC using a Perkin Elmer
Clarus 500 gas chromatograph with a Turbo-Mix HS 40
autosampler. GC conditions were as follows: injection
needle temperature: 85°C; transfer temperature: 70°C; oven
temperature: 80°C; pressure: 13 psi; sample equilibration
time: 22.3 min at 65°C. The system was operated by the
associated Total Chrome software, which also controlled data
handling and processing. A 100 μl portion of a standard
mixture of ethanol and acetaldehyde (1 mg/ml each), pre-
pared in the Laboratory by diluting suitable amounts of
ethanol and acetaldehyde previously stored at 4°C with cold
deionized water was diluted with 0.9 ml of cold water and
run as calibrant at the start of each analytical run. Initially,
this standard mixture was calibrated against a certified foren-
sic analytical 6-component standard containing ethanol and
acetaldehyde at 1 mg/ml each (Restek).
Pitfalls in acetaldehyde determination
One such pitfall is artifactual formation of acetaldehyde
from ethanol in the presence of blood, by a process depen-
dent on ethanol but not on its concentration (Truitt, 1970;
Eriksson et al., 1977; Eriksson, 1980). This was confirmed
in the present work in a control experiment in which
ethanol was added in final concentrations of 10–100 mM
to 0.1 ml portions of normal untreated rat blood. The
mixture was diluted to 1 ml with water in GC vials, which
were then sealed and analyzed as above. Acetaldehyde was
formed in amounts (in μM) of 61, 63, 64, 69, 61, 65 and
73 when ethanol was present at concentrations of 10, 20,
30, 40, 50, 75 and 100 mM, respectively. The acetaldehyde
formed was subtracted from the in vivo experimental
values observed.
Another problem in acetaldehyde determination is its
binding to haemoglobin and the consequently lower recov-
ery. The above authors recommended that, for rat blood, this
problem can be largely overcome by haemolysis of blood
samples (by dilution of one part of blood with nine parts of
water) prior to head-space GC analysis and by performing
control experiments to assess acetaldehyde recovery.
Acetaldehyde recovery from rat blood was reported by the
above authors to be 90% when acetaldehyde was added at a
final concentration of 100 μM. This was also confirmed in
the present study, in which a recovery value (expressed as
the mean percentage recovery ±SEM for three determi-
nations) of 90.5 ± 3.8 was observed with the above acet-
aldehyde concentration. Recoveries at other concentrations of
added acetaldehyde (25, 50, 150 and 200 μM) were 91.5 ±
2.8, 80.4 ±2.7, 84.5 ±2.4 and 85.4 ±1.9%, respectively. The
blood acetaldehyde concentration values in Fig. 2b were,
however, not corrected for full recovery because of the sim-
ultaneous presence of ethanol under the experimental con-
ditions of Fig. 2. Eriksson et al. (1977) found that, in the
presence of ethanol, the 90% recovery value rose to 105.4%
and it was therefore considered unnecessary to apply a
recovery factor, which in any case would have little effect on
the results in Fig. 3b.
We have thus addressed the above pitfalls in detail, taken
appropriate steps to circumvent them and are therefore confi-
dent of the validity of the blood acetaldehyde values reported
in the present study.
Determination of liver Trp and kynurenine metabolite
concentrations
Trp and its kynurenine metabolites were determined in liver by
our newly developed rapid isocratic high-performance liquid-
chromatographic procedure (Badawy and Morgan, 2010).
Briefly, a Perkin Elmer LC200 system consisting of a quatern-
ary pump, a column oven and a degasser was used with ultra-
violet and fluorimetric detection in series. The mobile phase
was a methanol: sodium dihydrogen phosphate mixture (27:73,
by vol) at a final pH of 2.0 or 2.8. The system was run isocrati-
cally using a Synergi 4 μ reverse-phase Fusion-RP80 A
column (250×4.6 mm) with guard column (Phenomenex).
Operation of the system, data processing and handling were all
Fig. 2. Time-course and dose–response effects of acute administration of
kynurenine metabolites on activity of the rat liver mitochondrial low km
ALDH activity was determined as described in the ‘Materials and Methods’
section at various times after intraperitoneal administration of a 10 mg/kg
dose of kynurenine metabolites (a) or at 1 h after 1–10 mg/kg doses (b).
Values are means±SEM (bars) for each group of 4–5 rats. Values at the
different time-intervals were compared statistically (t-test) with those at zero
time, whereas those with various doses were compared with the zero-dose
saline control, and the significance of the differences is expressed in the
relevant text of the ‘Results’ section. Abbreviations used: ALDH, aldehyde
dehydrogenase; KA, kynurenic acid; 3-HK, 3-hydroxykynurenine; 3-HAA,
3-hydroxyanthranilic acid.
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dard mixture of Trp and six of its kynurenine metabolites
(1 μg/ml each) was used as calibrant at the start of each run.
Results were corrected for full recovery.
Alcohol aversion test
Aversion to alcohol was assessed using the alcohol aversion
model of Garver et al. (2000). Briefly, individually housed
rats were allowed free access to food and water for 3 days.
Disulfiram (100 mg/kg), kynurenine metabolites (10 mg/kg
each) or vehicle were injected intraperitoneally once daily for
4 days. On the evening of the third day, water (but not food)
was withdrawn for 18 h, but was then replaced by a 6% (v/v)
ethanol solution, 2 h after the injection on the fourth day.
Body wt was measured daily and alcohol consumption was
monitored hourly for 4 h and levels were expressed cumulat-
ively over this duration in g/kg body wt.
Alcohol consumption and preference in alcohol-preferring
C57BL/6J mice
The potential effects of kynurenine metabolites on alcohol
consumption and preference by male alcohol-preferring
C57BL/6J mice were also studied. No attempt was made to
enhance alcohol preference by acclimatizing the mice to
increasing ethanol concentrations, as the purpose of our
study was to investigate aversion, which is the proposed
primary mechanism of action of kynurenine metabolites,
rather than preference. Accordingly, four groups (n= 8 each)
of individually housed mice were given free choice of drink-
ing water and a 10% (v/v) ethanol solution for 3 weeks to
establish their drinking patterns. Thereafter, mice received a
single daily intraperitoneal injection of kynurenine metab-
olites (10 mg/kg body wt each) or an equal volume of saline
for 5 days. Body wt and water and ethanol consumption
were recorded daily throughout the whole study duration.
Determined per kg body wt, daily alcohol consumption was
expressed in absolute amounts (g) and as a percentage of
total fluid intakes (% preference).
Statistical analysis
Enzymatic and other biochemical test results were compared
with those of control groups by the unpaired t test, whereas
alcohol consumption results were assessed initially by
one-way analysis of variance (ANOVA) and additionally for
within-group differences (time factor versus baseline values)
by paired t-tests, using Sigma Plot (Systat, UK), version 11,
with which graphics were prepared. For multiple group com-
parisons using this program, the Holm-Sidak test was
applied, as it is more powerful than the Tukey or Bonferroni
tests and can be used for both pairwise comparisons and
those versus a control group. Where the data failed the nor-
mality (Shapiro–Wilk) test, Kruskal–Wallis one-way
ANOVA on ranks was performed. A two-tailed level of sig-
nificance (P) was set at 0.05.
RESULTS
Inhibition of the rat liver mitochondrial low Km ALDH
activity by acute and chronic administration of kynurenine
metabolites
Acute time-course (Fig. 2a) and dose–response (Fig. 2b)
experiments were performed. Initially, we found that the
high Km ALDH activity (assayed in the presence of 5 mM
acetaldehyde) was not influenced by kynurenine metabolites.
Consequently all results reported in this section concern the
low Km activity. As shown in Fig. 2a, the mitochondrial low
Km ALDH activity was inhibited by all three kynurenine
metabolites after administration of a 10 mg/kg body wt dose.
At 0.5 h after administration, ALDH activity was inhibited
by 3-HK and KA by 45 and 37%, respectively (P =0.0267–
0.0024). Inhibition by all three metabolites was then main-
tained at 40–51% at 1 h. Thereafter, inhibition by KA
remained at this latter level until 4 h, whereas that by 3-HAA
continued to strengthen, reaching 84% at 4 h (P =0.0000).
With 3-HK, ALDH activity began to recover at 2 h, but
remained significantly inhibited at 2 and 3 h (by 30 and
17%, respectively; P=0.0128–0.0431).
Fig. 3. Effects of acute administration of kynurenine metabolites on rat
blood-ethanol and acetaldehyde concentrations. Rats received an
intraperitoneal injection (10 mg/kg body wt) of each kynurenine metabolite
or an equal volume of saline. One hour later, a similar injection of ethanol
(2 g/kg body wt as a 25% v/v solution in saline) was administered. Blood
samples were analyzed at the times indicated for ethanol and acetaldehyde
by head-space gas chromatography as described in the ‘Materials and
Methods’ section. Values for blood-ethanol (a) and acetaldehyde (b)a r e
means±SEM (bars) for each group of four rats. Test groups were compared
with the saline-pretreated control group (C) by the t-test. Abbreviations used
are as in Fig. 2.
654 Badawy et al.As shown in Fig. 2b, significant inhibition of 32–56%
(P = 0.0398–0.0008) of ALDH activity was observed at 1 h
after administration of a 1 mg/kg body wt dose of kynure-
nine metabolites. Maximum inhibition at 1 h was observed
with a 2.5 mg/kg dose of KA (86%) and with a 7.5 mg/kg
dose of 3-HK (59%) and 3-HAA (70%) (P =0.0035–
0.0001).
ALDH activity was also inhibited when a 10 mg/kg body
wt dose of the above 3 kynurenine metabolites was adminis-
tered daily for 8 days (data not shown). At 2 h after the
(final) injection on the 8th day, inhibition by KA, 3-HK and
3-HAA was 37%, 39% and 64% respectively (P =0.0292–
0.0007). Although this inhibition could very well be due to
the acute effect of kynurenine metabolites, it suggests that no
tolerance develops towards it after chronic treatment.
Inhibition of ALDH activity in vivo by acute administration
of kynurenine metabolites
ALDH activity in vivo was determined by measuring the
accumulation of acetaldehyde in blood following acute
ethanol administration. The results in Fig. 3 show blood-
ethanol (a) and acetaldehyde (b) concentrations after intraper-
itoneal administration of a 2 g/kg body wt dose of ethanol.
In saline-pretreated control rats, ethanol concentration rose to
35.8 mM at 1 h and to 37.1 mM at 2 h before declining to
26.0 mM at 3 h. None of the three kynurenine metabolites
exerted a significant effect on ethanol concentration at 1 h
(P >0.1). With 3-HAA, ethanol concentration resembled that
in saline-treated controls at 2 and 3 h. By contrast, ethanol
concentration at 2 and 3 h after ethanol administration was
significantly decreased by pretreatment of rats with KA and
3-HK, by 24–27% (P =0.05–0.0175).
Blood acetaldehyde concentration following ethanol
administration (Fig. 3b) to saline-pretreated control rats
remained at a constant level of 45–47 μM, suggesting a
constant rate of ethanol and acetaldehyde oxidation over
the 1–3 h observation period. Pretreatment of rats with KA
increased acetaldehyde concentration by 109, 125 and
115%, respectively (P =0.0104–0.0029). 3-HK induced a
stronger elevation of acetaldehyde concentration, of 180,
174 and 202%, respectively at 1–3 h after ethanol adminis-
tration (P =0.0017–0.0000), whereas with 3-HAA, the
elevation of acetaldehyde concentration was modest (42, 34
and 56%, respectively), and not significant (P >0.1). The
elevation of blood acetaldehyde concentration by 3-HK was
significantly greater than that by KA at 1–3h ( P= 0.05–
0.0095).
Demonstration of aversion to alcohol after administration
of kynurenine metabolites and disulfiram
In the aversion model of Garver et al. (2000), rats treated
with the classical ALDH inhibitor disulfiram consumed
equal amounts of the ethanol drinking solution as control
animals during the first hour of the test. Thereafter, alcohol
consumption by disulfiram-treated rats remained static,
unlike that by controls, which continued to increase cumulat-
ively up to the fifth hour. The results in Fig. 4a, show that
disulfiram actually inhibited alcohol consumption signifi-
cantly and maximally during the first hour (by 51%; P
0.0351, paired t-test), thereafter the animals continued to
drink the ethanol solution, but to a lesser degree than
controls. Thus, the inhibition of ethanol consumption by dis-
ulfiram was maintained for two more hours, as 45–46% (P =
0.0158–0.0138), but, at 4 h, the 37% decrease was not sig-
nificant. The results in Fig. 4b show that kynurenine metab-
olites also inhibited alcohol consumption in this model
significantly (P =0.05–0.005) over the first 3 h. Thus, as was
the case with disulfiram, inhibition of alcohol consumption
was strongest at 1 h after administration of KA, 3-HK and
3-HAA (by 28, 26 and 50%, respectively). Inhibition
remained significant at 2 and 3 h, but, by 4 h, only that by
KA was still significant.
It will be noted from the data in Fig. 4 that alcohol con-
sumption by control rats in the disulfiram experiment
(Fig. 4a) is lower than that of the control animals in the
kynurenine metabolite experiment (Fig. 4b). This is almost
certain to be due to the use of dimethylformamide, along
with saline, to dissolve disulfiram, rather than to variations
among different batches of animals, because, as will be seen
in the accompanying paper (Badawy et al., 2011), the
control data obtained in animals given saline only in two
different experiments were broadly similar to those in the
present experiment with kynurenines.
Fig. 4. Inhibition of alcohol consumption by disulfiram (a) and kynurenine
metabolites (b) in a rat alcohol aversion model Experimental details are as
described in the ‘Materials and Methods’ section. Ethanol consumption was
monitored hourly for 4 h and is expressed in g/kg body wt cumulatively.
Values are means±SEM (bars) for each group of 4–6 rats. Abbreviations
are as in Fig. 3.
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As no attempt was made to enhance alcohol preference by
acclimatizing the mice to increasing ethanol concentrations,
there were wide variations in levels of consumption of the
10% (v/v) ethanol solution, with ~37–50% of the mice in
each group consuming >10 g/kg/day, and showing >50%
preference, with the remainder consuming up to 7 g/kg/day
with a level of preference <32%. To establish comparability
between group at baseline (Day 0), six mice from each group
were selected whose results are shown in Fig. 5. As shown,
the % preference (Fig. 5a) and absolute ethanol intake in g/
kg body wt (Fig. 5b) were broadly similar across groups at
baseline, with no significant differences (P> 0.1). In the
saline-treated control group, preference remained stable for 4
days and the decrease on Day 5 did not reach statistical sig-
nificance (P =0.095). By contrast, preference decreased in
mice receiving the three kynurenine metabolites, with
3-HAA causing the largest decrease. Compared with base-
line, the decrease in the % preference with 3-HAA (23–46%)
was significant on all days (P=0.043–0.009), except Day
4. With 3-HK and KA, only the decreases on Days 4 and/or
5 (19–39%) were significant (P =0.05–0.011). When the %
preference values with kynurenine metabolites were com-
pared with those of the control group, significant decreases
were also observed with 3-HK (37%) on Day 4, with KA
(26–30%) on Days 1 and 4 and with 3-HAA (26–36%) on
Days 1–5( P= 0.05–0.0075).
When alcohol consumption was expressed in absolute
amounts (g/kg body wt) (Fig. 5b), a broadly similar pattern
emerged, with 3-HAA causing the greatest decrease in
alcohol intake. However, the only significant differences
were those compared with the saline controls for KA on
Days 1 and 4 and for 3-HAA on Days 1 and 5 (31–45%;
P =0.021–0.001).
Hepatic concentrations of kynurenine metabolites after their
administration
Hepatic concentrations of KA, 3-HK and 3-HAA were deter-
mined after acute administration of each individual com-
pound in the same rats in which ALDH activity was
assessed. Although concentrations of other kynurenine
metabolites and of Trp were also determined, these are not
reported here, as their relevance largely falls outside the
Fig. 5. Effects of repeated administration of kynurenine metabolites on
alcohol consumption and preference in male alcohol-preferring C57BL/6J
mice Experimental details are as described in the ‘Materials and Methods’
section. Alcohol consumption was monitored daily and is expressed (per kg
body wt) for each group from Day 0 (before the injections) onwards, both as
a preference % (a) and in g amounts (b). Values are means±SEM (bars) for
each group of six mice. For statistical comparisons, see the relevant text in
the ‘Results’ section.
Fig.6. Hepatic kynurenine metabolite concentrations after their acute
administration Kynurenine metabolite concentrations were determined as
described in the ‘Materials and Methods’ section in livers of the same rats
undergoing the time-course (a) and dose–response (b) experiments with
ALDH reported in Fig. 2. Values are means±SEM (bars) for each group of
five rats. Abbreviations and comparisons are as in Fig. 2.
656 Badawy et al.scope of the present paper. When a 10 mg/kg body wt dose
of the three kynurenine metabolites was administered
(Fig. 6a), maximum increases (of 4.2–7.3-fold) in their con-
centrations were observed at 1 h (P = 0.0002) and were
maintained for 3–4 h. Dose-dependent increases in liver
kynurenine metabolite concentrations were observed at 1 h
(Fig. 6b) in the 1–10 mg/kg dose-range with KA and 3-HK.
However, with 3-HAA, the maximum increase was observed
with the 5 mg/kg dose. Baseline [3-HAA] in the time-course
experiment was lower than that in the dose–response one.
This is most likely due to variations across different animal
batches, as the relative increases in this metabolite concen-
tration at 1 h after administration of the 10 mg/kg dose were
similar in both experiments (2.67 and 2.97-fold,
respectively).
Animal body weights during repeated administration
of kynurenine metabolites and disulfiram
Body wt was measured in chronic experiments, not only to
determine daily dose levels, but also as a measure of animal
welfare and safety of administered compounds. In the
alcohol aversion study in which compounds were injected
once daily for 4 days, both rats treated with kynurenine
metabolites and their saline-treated controls gained weight at
the normal rate during the first 3 days. However, small
losses of 6–9% were observed in both control and test rats
on the morning of the final (fourth) day, compared with
body weights the day before, almost certainly due to introdu-
cing a water-deprivation regimen during the preceding 18 h.
In the aversion experiments with disulfiram and its control
rats receiving the vehicle (saline: dimethylformamide, 1:1),
both control and test rats showed a small wt loss (2.8 and
4.2%) on Day 3, compared with Day 1, presumably due to
this solvent, in addition to a 3–6% wt loss following the
water-deprivation period, as was the case with kynurenine
metabolites and their pure saline control.
In the chronic study of changes in rat liver ALDH activity
in which kynurenine metabolites were administered daily for
8 days, changes in body weights were also recorded. As
shown in Fig. 7a, all groups gained wt significantly (P =
0.001), with the gains by control rats reaching 26% on Day
8. Rats receiving KA and 3-HK also gained wt at a rate
close to that of controls (respectively 21 and 24% on Day 8).
3-HAA-treated rats, however, gained wt less strongly, achiev-
ing only a 10% wt gain on Days 6–8. All animals appeared
to tolerate kynurenine metabolites and showed no adverse
reactions or unusual behaviours.
Body wt was also recorded for mice during the prefer-
ence study. The body weights of all mice (n=32) at the
start of the study (mean± SEM in g) (26.83 ± 0.25) rose by
5% during the 21-day free choice period to reach 28.09 ±
0.23 g (P =0.003) on Day 0 of the 5-day drug adminis-
tration experiment. As shown in Fig. 7b, body weights
remained stable over the 5-day period and none of the
changes in the control and test groups was significant when
compared with the zero day value (P >0.9). This is
reflected in the small (not exceeding 2.5%), but insignifi-
cant, gains observed in the control group and those receiv-
ing 3-HK and KA and in the small (2%) and insignificant
loss in mice of the 3-HAA group. As was the case with
rats, mice appeared healthy and showed no adverse reac-
tions or unusual behaviors.
DISCUSSION
Inhibition of ALDH activity after administration
of kynurenine metabolites
The present results have established the ability of three Trp
metabolites of the kynurenine pathway, namely KA, 3-HK
and 3-HAA to inhibit the rat liver mitochondrial low Km
activity of ALDH after acute administration (Fig. 2) and that
no tolerance to this inhibition develops after repeated admin-
istration. Inhibition was significant with a dose as small as 1
mg/kg body wt (Fig. 2b) and was maximal at 1 h, except
after 3-HAA (Fig. 2a). The hepatic concentrations of these
metabolites also reached maximum values at 1 h (Fig. 5a) in
line with the maximum inhibition. The hepatic concen-
trations observed (Fig. 5) are well in excess of the 2 μM con-
centration previously shown to cause 40–55% inhibition in
vitro (Badawy and Morgan, 2007).
Fig. 7. Body weights of rats and mice during chronic treatment with
kynurenine metabolites on Day 1 (rats) or Day 0 (mice), animals received
single daily intraperitoneal injections of saline or kynurenine metabolites
(10 mg/kg each) for 8 (rats) or 5 (mice) days. Body wt was monitored daily
each morning and is expressed in g for both rats (a) and mice (b). Values
are means±SEM (bars) for each group of six rats or eight mice. For
abbreviations, see Fig. 5.
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longest durations studied). With 3-HK, ALDH inhibition,
which was maximal at 1 h, began to lessen thereafter,
suggesting that it is short-lived and hence reversible.
However, with KA and 3-HAA, inhibition either remained at
its maximal value or gained in strength, suggesting a longer
duration and a possible irreversible nature. With disulfiram,
its irreversible inhibition (Marchner and Tottmar, 1978)i s
characterized by a prolonged duration (7–10 days) after a
single dose (see, Brien and Loomis, 1985). Kinetic studies
are clearly required to establish the mechanism(s) of the
ALDH inhibition by these kynurenine metabolites.
Inhibition of ALDH activity in vivo by administration
of kynurenine metabolites
3-HK and KA also inhibited ALDH activity in vivo,a s
suggested by their strong elevation of blood acetaldehyde
concentration after ethanol administration (Fig. 3b), whereas
3-HAA caused only a modest increase. As blood-ethanol
concentration at 1 h was not influenced by any of the three
kynurenine metabolites (Fig. 3a), we conclude that ethanol
kinetics were not altered up to this time-point. Thereafter,
blood-ethanol concentration was also little altered by
3-HAA, but was significantly decreased by KA and 3-HK,
suggesting acceleration of ethanol metabolism by acting on
alcohol dehydrogenase or other ethanol-oxidizing enzymes,
or through other mechanisms. Further work is required to
elucidate the nature of this effect. In relation to a potential
acceleration of ethanol metabolism by KA, Lapin and Politi
(1994) speculated as to whether the shortening of
ethanol-induced sleep time by indol-3-ylpyruvic acid could
be due to its conversion to KA. The elevation of blood acet-
aldehyde concentration by 3-HK and KA strongly suggests
that both compounds inhibit AlDH activity in vivo,t h u s
further corroborating their effects in vitro (Badawy and
Morgan, 2007) and after administration (Fig. 2 in the present
work).
Induction of aversion to alcohol by kynurenine metabolites
The alcohol aversion model of Garver et al. (2000) is a
variant of the conditioned taste aversion paradigm in which a
novel taste (that of alcohol introduced for the first time) is
associated with a noxious condition (the disulfiram-ethanol
reaction). That a robust conditioned taste aversion quickly
develops under such conditions has been demonstrated
(Nolan et al., 1997; Scalera et al., 1997; Barber et al., 1998;
Yasoshima and Yamamoto, 1998). We have successfully
confirmed the above authors’ findings with disulfiram and
demonstrated the ability of our three kynurenine metabolites
to induce aversion to alcohol (Fig. 4). Two differences from
the findings by Garver et al. (2000) with disulfiram were,
however, observed: (a) the inhibition of alcohol consumption
by disulfiram was already significant and strongest at the 1 h
observation period, whereas the above authors observed no
inhibition at 1 h; (b) our disulfiram-treated rats continued
thereafter to drink more fluid, though less than controls,
whereas alcohol consumption by rats studied by the above
authors remained static at the 1 h level. The earlier inhibition
by disulfiram of alcohol consumption in our study may be
due to the more rapid absorption of the drug solution after
intraperitoneal, when compared with that of the drug
suspension after oral, administration as reported by the above
authors.
Both 3-HK and KA were equally effective, whereas
3-HAA caused a stronger inhibition of alcohol consumption.
This is somewhat surprising, as this metabolite did not cause
a significant increase in blood acetaldehyde concentration
(Fig. 3b), even-though it caused the strongest inhibition of
AlDH activity after administration (Fig. 2a). It is possible
that additional factors are involved in the aversive effects of
3-HAA. Alternatively, it is possible that 3-HAA may also
exert an inhibitory effect on ethanol oxidation, which, super-
imposed on its ALDH inhibition, may have led to the small
insignificant elevation of blood acetaldehyde concentration.
These possibilities require investigation.
Alcohol consumption was also decreased in alcohol-
preferring C57 mice. In particular, the % preference, and to a
lesser extent the absolute amount of alcohol consumed, were
decreased, with 3-HAA causing the strongest decreases.
However, due to the wide individual variations between mice
and the small numbers used, these results, though comp-
lementary to the aversion results, can only be considered
preliminary.
General safety of kynurenine metabolites
The present results have shown that a 10 mg/kg body wt
dose of the three kynurenine metabolites studied exerted no
undesirable side effects or toxicity in rats or mice when
administered intraperitoneally once or once daily over a 4–8
day period. KA is the endogenous antagonist of the
N-methyl-D-aspartate type of glutamate receptors (Stone,
1993) and doses of it as large as 500–1500 mg/kg body wt
are tolerated by mice when administered subcutaneously;
only sedation has been observed with these large doses
(Rasmussen et al., 1991). Relatively smaller intraperitoneal
doses of KA (up to 200 mg/kg) have been shown to be
anxiolytic (Lapin, 1996, 1998). The potential toxicity of
3-HK and 3-HAA is a more controversial issue. 3-HAA has
been reported (Morita et al., 2001) to induce apoptosis in
monocyte-derived cells stimulated by interferon-γ, but at a
concentration (200 μM) unlikely to be reached physiologi-
cally or even pathologically. Also this effect is limited to the
THP-1 and U937, but not four other, cell lines. Under these
conditions, the above authors could not detect an apoptotic
effect for 3-HK at a similar concentration. In fact, a 250 mg/
kg dose of 3-HK has been administered subcutaneously to
rats with no reported side effects (Luthman et al., 1996). The
fact that our rats treated daily with 3-HK for 8 days gained
weight at a rate similar to controls suggests that this metab-
olite does not cause signs of toxicity at the dose level used.
Only 3-HAA caused a significant weight loss, suggesting
some degree of toxicity at the 10 mg/kg dose level used,
although this was not visibly apparent.
3-HK, which can be taken-up by the brain (Speciale and
Schwarcz, 1990; Fukui et al., 1991), has been suggested to
be neurotoxic, as it can promote neuronal cell death by pro-
ducing hydrogen peroxide (Okuda et al., 1996) (an effect
that has not so far been duplicated in vivo) and in view of
the earlier finding of its elevated levels in post-mortem
brains of patients with Huntington’s disease (Reynolds and
Pearsons, 1993), although levels of 3-HK and 3-HAA in
blood of living Huntington’s patients (Stoy et al., 2005) and
658 Badawy et al.also those with chronic brain injury (Mackay et al., 2005)
have been shown to be lower than in controls. Stoy et al.
(2005) suggested that, although blood [3-HK] may not
reflect that in brain, it is also possible that oxidative stress in
Huntington’s disease may trigger a secondary activation of
the kynurenine pathway in the brain. Also, although the find-
ings by Okuda et al. (1996) support a pro-oxidant effect of
3-HK, it has been reported (Goda et al., 1999) that, of all
Trp and serotonin metabolites, both 3-HK and 3-HAA
possess the highest antioxidant properties, with a
radical-scavenging reactivity and inhibition of lipid peroxi-
dation greater than those by α-tocopherol (vitamin E).
Furthermore, as Morita et al. (2001) suggested that the apop-
totic effect of 3-HAA is due to generation of H2O2, the
failure of 3-HK to induce apoptosis in their study further
suggests that this kynurenine metabolite does not generate
H2O2 even at a 200 μM concentration. Nor are hydroxyl rad-
icals involved in 3-HK oxidation by methaemoglobin with
H2O2 (Ishii et al., 1992). Further evidence of an antioxidant
role for 3-HK and 3-HAA has been obtained in vitro in rat
cerebral cortex and cultured C6 glioma cells with the demon-
stration (Leipnitz et al., 2007) that both metabolites prevent
lipid peroxidation in the brain, decrease peroxy radical
induction, and prevent glutaric acid-induced free radical for-
mation. Furthermore, the role of 3-HAA as a modulator of
the immune system is increasingly recognized with, among
others, its ability to decrease the release of cytokines, to
exert direct antiproliferative effects, suppress the activation of
pro-inflammatory transcription factor NFκB (nuclear factor
kappa-light-chain-enhancer of activated B cells), and inhibit
nitric oxide synthase (for review, see Darlington et al., 2010
and references cited therein).
General conclusions and comments
We have established proofs of mechanism (inhibition of the
target enzyme ALDH after administration and in vivo) and
principle (induction of aversion to alcohol) in the present
preclinical developmental study with metabolites of the
amino acid Trp of the kynurenine pathway. Previous studies
(Lapin et al., 1991) have established a prior art for the use of
KA in alcoholism treatment, whereas no prior art exists for
the use of 3-HK or 3-HAA, for which a US patent is
expected shortly. As the most potent AlDH inhibitor in vivo
and the immediate precursor of 3-HAA, 3-HK is of particu-
lar interest, but its potential clinical use in alcoholism treat-
ment requires further developmental studies by interested
parties. A more immediate and near clinic-ready alternative
is the use of its parent compound Trp under appropriate
metabolic conditions, evidence for which is presented in the
following paper (Badawy et al., 2011).
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